Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment. An international ...

A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...

Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product ...

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S.

YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...

LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific ...

NANTES, France--(BUSINESS WIRE)--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated ...